Neurogene Inc. (NGNE)
Nasdaq: NGNE · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 24, 2026 | Mar 24, 2025 | Mar 18, 2024 | Mar 20, 2023 | Mar 1, 2022 | Mar 25, 2021 | Mar 12, 2020 | Mar 7, 2019 | Mar 12, 2018 | Mar 9, 2017 |
| Revenue | 0 | 925 | 0 | · | · | · | · | 25,000 | · | · |
| For lenders | ||||||||||
| Net interest income | · | · | · | 1,582 | 19 | · | · | · | · | · |
| Research and development | 75,011 | 60,917 | 44,394 | 47,505r | 39,162 | 24,344 | 4,417 | 41,789 | 36,267 | 28,382 |
| General and administrative | 28,317 | 22,613 | 11,189 | 9,012r | 21,536 | 17,210 | 18,826 | 15,835 | 14,852 | 9,263 |
| Total operating expenses | 103,328 | 83,530 | 55,583 | 56,517r | 60,698 | · | 70,959 | 57,624 | 51,119 | 37,645 |
| Operating income | -103,328 | -82,605 | -55,583 | -56,517r | -60,698 | -33,728 | -70,959 | -32,624 | -51,119 | -37,645 |
| Interest expense | 5 | 12 | 12 | 2 | · | · | 1 | 4 | 4 | 1 |
| Interest and investment income | 11,547 | 8,467 | 2,951 | 1,337 | 19 | 490 | 1,542 | 1,563 | 998 | 619 |
| Other income (expense), net | · | · | · | · | -12 | -44 | -9r | 1,043 | 940 | 644 |
| Total non-operating income (expense) | 12,977 | 7,461 | · | -42 | -13r | 451 | 1,517 | 1,039 | 936 | 643 |
| Income before income taxes | -90,351 | -75,144 | -36,317 | -55,189r | -60,692 | -33,277 | -69,442 | -31,585 | -50,183 | -37,002 |
| Income tax expense | 0 | 0 | · | · | · | · | · | · | · | 0 |
| Net income including non-controlling interests | · | · | · | · | · | · | -69,442 | -31,585 | -50,183 | -37,002 |
| Net income | -90,351 | -75,144 | -36,317 | -55,189r | -60,692 | -33,277 | -69,442 | -31,585 | -50,183 | -37,002 |
| Net income to common shareholders | · | · | · | · | · | · | · | · | · | -37,002 |
| Earnings per share, basic | -4.24 | -4.28 | · | -1.04 | -1.10 | -0.64 | · | · | · | · |
| Earnings per share, diluted | -4.24 | -4.28 | · | -1.04 | -1.10 | -0.64 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 |
| Weighted average shares, basic | 21,326,283 | 17,567,082 | · | 55,221,161 | 55,041,662 | 51,825,022 | · | · | · | · |
| Weighted average shares, diluted | 21,326,283 | 17,567,082 | · | 55,221,161 | 55,041,662 | 51,825,022 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 51,825,022 | 27,030,355 | 23,519,508 | 23,450,315 | 18,893,515 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpense
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted